Financial Data and Key Metrics Changes - Total revenue for Q3 2024 was $2.9 billion, representing a 29% year-over-year growth [7][24] - Adjusted EBITDA was $151 million, reflecting a 16% growth year-over-year [7][27] - The company raised its total revenue guidance for 2024 to a range of $11.0 billion to $11.3 billion and adjusted EBITDA guidance to $580 million to $585 million [32][33] Business Line Data and Key Metrics Changes - Pharmacy Solutions revenue was $2.3 billion, achieving a 35% growth year-over-year [24] - Infusion and Specialty business revenue grew 42% year-over-year, while home and community pharmacy revenue increased by 19% [11][24] - Provider Services segment revenue grew 10% year-over-year, with home healthcare revenue increasing by 13% and community and rehab care revenue growing by 8% [25][16] Market Data and Key Metrics Changes - Total scripts dispensed year-to-date showed a 15% growth compared to last year, driven by a 36% increase in Specialty scripts [11] - The company reported a 16% increase in average daily census in home healthcare, reaching over 46,000 [19] Company Strategy and Development Direction - The company continues to focus on M&A and de novo expansion, with a strong acquisition pipeline to augment organic growth [10] - BrightSpring aims to drive operational best practices and volume growth in attractive markets while providing high-quality, lower-cost care [22] - The company is investing in its Infusion business to improve operational efficiencies and profitability, expecting results from these investments in 2025 [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver on its updated 2024 outlook, citing broad-based strength across Pharmacy and Provider segments [21][22] - The management highlighted the positive impact of changes in Part D on drug affordability, which is expected to drive volume growth [57][58] Other Important Information - The company received a 3-year CARF accreditation in Indiana, indicating high-quality service delivery [18] - A new independent director, Dr. Steve Miller, was added to the Board, bringing extensive clinical leadership experience [23] Q&A Session Summary Question: Margin expectations for Q4 - Management expects Q4 to be the highest margin quarter due to various factors including the launch of a generic drug and onboarding of new customers [36] Question: Impact of biosimilars and pricing adjustments - Management indicated minimal impact from biosimilars in their Specialty pharmacy business, focusing on operational initiatives for future growth [38] Question: Update on large long-term care operator negotiations - Successful onboarding of a large customer across over 200 buildings was confirmed, with expectations of increased EBITDA as costs decrease [42][44] Question: Impact of the Inflation Reduction Act - Management noted that the IRA's impact is primarily seen in 2026, with no significant risk identified for the company [48][49] Question: Growth drivers for 2025 - Management highlighted multiple growth drivers including specialty pharmacy, infusion, home health, and hospice services, expecting continued double-digit growth [66][73] Question: Capital deployment priorities - The company plans to focus on small, accretive transactions in pharmacy and provider services, maintaining a balanced approach to acquisitions and de novo expansions [84][86]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41938 | --- | |----------------------------------------------------------------------------| | | | | | | | Delaware | | (Stat ...

LOUISVILLE, Ky., November 1, 2024 — BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the third quarter ended September 30, 2024, and increases 2024 revenue and Adjusted EBITDA 1 guidance. 1 BrightSpring Health Services, Inc. Reports Third Quarter 2024 Financial Results and Increases Full Year 2024 Guidance Financial Highlights • Net Revenue of $2,9 ...

LOUISVILLE, Ky., Nov. 01, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the third quarter ended September 30, 2024, and increases 2024 revenue and Adjusted EBITDA1 guidance. Financial Highlights Net Revenue of $2,907 million, up 28.8% compared to $2,257 million in the third quarter of 2023.Net loss of $9.0 million, compa ...

Overview of FMR LLC (Trades, Portfolio)'s Recent Transaction On September 30, 2024, FMR LLC (Trades, Portfolio) made a significant addition to its investment portfolio by acquiring 18,498,153 shares of BrightSpring Health Services Inc (BTSG, Financial). This transaction, executed at a price of $14.68 per share, reflects a strategic move by the firm, aligning with its broader investment objectives. The trade not only increased FMR LLC (Trades, Portfolio)'s total holdings in BTSG but also adjusted its portfol ...

LOUISVILLE, Ky., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG) announced today that it plans to release its third quarter 2024 financial results on Friday, November 1, 2024, prior to the Company's earnings conference call, which will be held at 8:30 a.m. ET on the same day. To participate in the conference call, please register here before the 8:30 a.m. ET start. A live and archived webcast of the call will be available on the Company's ...

LOUISVILLE, Ky., Sept. 30, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services ("BrightSpring" or "the Company") (NASDAQ: BTSG), a leading provider of home- and community-based health services for complex populations, today announced that Dr. Steve Miller was appointed as a Class II member of the Board of Directors. Dr. Miller will also serve as a member of the Board's Audit Committee and as the chair of the Board's Quality & Compliance and Governance Committee. As a nationally recognized advocate for gre ...

PITTSBURGH, Sept. 12, 2024 /PRNewswire/ -- North Central Florida Hospice, Inc. and Haven Medical Group, LLC (collectively "Haven Hospice"), a Florida-based company for comprehensive hospice care services in 18 counties in north central Florida completed its sale of select assets to BrightSpring Health Services (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, effective September 1, 2024. Haven Hospice's Mission remains unchanged: "Honoring life by provid ...

LOUISVILLE, Ky., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services ("BrightSpring" or "the Company") (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced that it completed the acquisition of the assets of North Central Florida Hospice, Inc. and Haven Medical Group, LLC (collectively "Haven Hospice"), a Florida-based company holding a Certificate of Need (CON) for comprehensive hospice care services in 18 counties in north centr ...

NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG) on behalf of BrightSpring stockholders. Our investigation concerns whether BrightSpring has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On or around January 25, 2024, Bright ...